Pourab Roy
YOU?
Author Swipe
View article: A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia Open
SY-2101 is a novel oral formulation of arsenic trioxide (ATO). Although IV ATO in combination with all trans retinoic acid is highly efficacious in treating acute promyelocytic leukemia (APL), there remains a significant unmet need due to …
View article: FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease Open
The FDA approved nivolumab on May 20, 2021, for the adjuvant treatment of completely resected (negative margins) esophageal or gastroesophageal junction cancer (EC/GEJC) in patients who had residual pathologic disease following chemoradiot…
View article: FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations Open
The FDA approved capmatinib and tepotinib on May 6, 2020, and February 3, 2021, respectively. Capmatinib is indicated for patients with metastatic non–small cell lung cancer (mNSCLC) whose tumors have a mutation leading to mesenchymal–epit…
View article: Efficiency of naive estimators for accelerated failure time models under length‐biased sampling
Efficiency of naive estimators for accelerated failure time models under length‐biased sampling Open
In prevalent cohort studies where subjects are recruited at a cross‐section, the time to an event may be subject to length‐biased sampling, with the observed data being either the forward recurrence time, or the backward recurrence time, o…
View article: Response of single leukemic cells to peptidase inhibitor therapy across time and dose using a microfluidic device
Response of single leukemic cells to peptidase inhibitor therapy across time and dose using a microfluidic device Open
Microfluidic single-cell assays of peptide degradation were performed at varying inhibitor doses, and the resulting data were analyzed by regression modeling to reveal biological effects.
View article: Non-parametric and Semi-parametric Estimation in Forward and Backward Recurrence Time Data
Non-parametric and Semi-parametric Estimation in Forward and Backward Recurrence Time Data Open
In prevalent cohort survival studies where subjects are recruited at a cross-section and followed prospectively in time, the observed event times are length-biased and further follow a multiplicative censoring scheme. For such studies ther…
View article: Efficient estimation of accelerated lifetime models under length-biased sampling
Efficient estimation of accelerated lifetime models under length-biased sampling Open
In prevalent cohort studies where subjects are recruited at a cross-section, the time to an event may be subject to length-biased sampling, with the observed data being either the forward recurrence time, or the backward recurrence time, o…
View article: Efficient estimation of accelerated lifetime models under length-biased\n sampling
Efficient estimation of accelerated lifetime models under length-biased\n sampling Open
In prevalent cohort studies where subjects are recruited at a cross-section,\nthe time to an event may be subject to length-biased sampling, with the\nobserved data being either the forward recurrence time, or the backward\nrecurrence time…